← Back to Search

Hematopoietic Stem Cell Transplantation

TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for Bone Marrow Transplant

Phase 2

Waitlist Available

Research Sponsored by Children's Hospital Medical Center, Cincinnati

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing whether a new way to do a stem cell transplant, which uses a device to remove some cells from the transplanted blood, is safe and effective in children and young adults with cancer or other blood disorders.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Infusion-related Reactions

Secondary outcome measures

Engraftment and Sustained Donor Chimerism

GVHD-free Survival

Number of Participants With Acute GVHD

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: TCRαβ+/CD19+ depleted HSCTExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor

815 Previous Clinical Trials

6,531,576 Total Patients Enrolled

Media Library

TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) (Hematopoietic Stem Cell Transplantation) Clinical Trial Eligibility Overview. Trial Name: NCT04088760 — Phase 2

Bone Marrow Transplant Research Study Groups: TCRαβ+/CD19+ depleted HSCT

Bone Marrow Transplant Clinical Trial 2023: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) Highlights & Side Effects. Trial Name: NCT04088760 — Phase 2

TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) (Hematopoietic Stem Cell Transplantation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04088760 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities to enroll in this medical trial currently available?

"This trial, which has been advertised since September 16th 2019 and recently updated on the 21st of September 2021, is now actively seeking participants."

Answered by AI

To what extent is TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) a safe procedure for people?

"The safety of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) was assessed as a 2, since there is preliminary data that suggests its safety but no evidence to back efficacy."

Answered by AI

What is the current aggregate of participants in this medical experiment?

"Correct. According to the information posted on clinicaltrials.gov, this study is actively seeking participants with an initial posting date of September 16th 2019 and a recent update as of September 21st 2021. 80 patients must be enrolled from one medical site for the trial to move forward."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

2019. "TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04088760.